Evidence map›Paper›PMID 37119804›Full record

ArticleGenetics2023

Cell state-dependent chromatin targeting in NUT carcinoma.

Artyom A Alekseyenko, Barry M Zee, Zuzer Dhoondia, Hyuckjoon Kang, Jessica L Makofske, Mitzi I Kuroda

Open access · greenAbstract read
In one paragraph

Article in Genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 77% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Artyom A AlekseyenkoDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Barry M ZeeDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Zuzer DhoondiaDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Hyuckjoon KangDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Jessica L MakofskeDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Mitzi I KurodaDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Harvard University · USBrigham and Women's Hospital · USCell Signaling Technology (United States) · US

Funding

Epigenetic regulation of transcriptional programmingR35GM126944 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI KURODA, MITZI I · 2018 to 2022
$3.3M
NIGMS NIH HHS R35 GM126944
6 · The paper itself

Abstract

Aberrant transcriptional programming and chromatin dysregulation are common to most cancers. Whether by deranged cell signaling or environmental insult, the resulting oncogenic phenotype is typically manifested in transcriptional changes characteristic of undifferentiated cell growth. Here we analyze targeting of an oncogenic fusion protein, BRD4-NUT, composed of 2 normally independent chromatin regulators. The fusion causes the formation of large hyperacetylated genomic regions or megadomains, mis-regulation of c-MYC, and an aggressive carcinoma of squamous cell origin. Our previous work revealed largely distinct megadomain locations in different NUT carcinoma patient cell lines. To assess whether this was due to variations in individual genome sequences or epigenetic cell state, we expressed BRD4-NUT in a human stem cell model and found that megadomains formed in dissimilar patterns when comparing cells in the pluripotent state with the same cell line following induction along a mesodermal lineage. Thus, our work implicates initial cell state as the critical factor in the locations of BRD4-NUT megadomains. These results, together with our analysis of c-MYC protein-protein interactions in a patient cell line, are consistent with a cascade of chromatin misregulation underlying NUT carcinoma.

Indexed as

CarcinomaChromatinBromodomain Containing ProteinsCell Cycle ProteinsCell Line, TumorHumansNuclear ProteinsTranscription FactorsBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsChromatinNuclear ProteinsTranscription FactorsacetylationBRD4megadomainsMYCNUT carcinoma

Identifiers

PMID37119804
PMCPMC10691748
OpenAlexW4367366195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.